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Compelling evidence from clinical 
trials testing multiple immunothera-
peutic interventions demonstrates that 
the immune system has the potential to 
inhibit oncogenesis and tumor progres-
sion. Thus, to generate neoplastic lesions, 
malignant cells must evolve strategies that 
allow them to evade recognition and elim-
ination by tumor-infiltrating cytotoxic 
T lymphocytes (CTLs). These escape 
mechanisms are multiple, influencing 
most, if not all, the steps that underpin 
a productive immune response, from the 
presentation of tumor-associated antigens 
(TAAs) to the susceptibility of cancer 
cells to lysis. The mechanisms of immu-
noescape related to the effector phase of 
cellular immunity have been extensively 
described. Conversely, how malignant cells 
avoid the elicitation of cellular immune 
responses has been investigated to a lim-
ited extent, in spite of an increasing body 
of data showing that target cells have a 
major impact on the clinical response to T 
cell-based immunotherapy. Here, we will 
comment on immunoescape mechanisms 
stemming from defects in the signal trans-
duction and activator of transcription 
(STAT) signaling pathway, emphasizing 
our recent results in models of head and 
neck squamous cell carcinoma (HNSCC).
We selected HNSCC for our studies 
since it employs several of the immunoes-
cape mechanisms generally harnessed by 
malignant cells. Moreover, the etiology 
of HNSCC encompasses chemical carci-
nogenesis as well as viral carcinogenesis, 
hence providing a broad working model. 
One common mechanism whereby can-
cer cells evade immune recognition is the 
downregulation of MHC class I antigen-
processing machinery (APM) components 
such as transporter of antigen processing 
1, ATP-binding cassette, sub-family B 
(MDR/TAP) (TAP1), TAP2 and pro-
teasome (prosome, macropain) subunit, β 
type, 9 (PSMB9, best known as LMP2), 
which results in limited TAA presenta-
tion.1 These defects are clinically relevant2 
since they are often associated with poor 
disease outcome among patients affected 
by a variety of neoplasms. Furthermore, 
they have a negative impact on T cell-
based as well as on antibody-based 
immunotherapy, at least in settings in 
which TAA-targeting antibodies trigger 
or enhance TAA-specific T-cell immune 
responses.
In HNSCC cells, the downregulation 
of the APM is mediated (at least in part) 
by the epidermal growth factor recep-
tor (EGFR)-induced activation of pro-
tein tyrosine phosphatase, non-receptor 
type 11 (PTNP11, best known as SHP2), 
which dephosphorylates (hence inactivat-
ing) signal transducer and activator of 
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The epidermal growth factor receptor (eGFr) supports the escape of malignant cells from immunosurveillance by 
inhibiting the activation of signal transducer and activator of transcription 1 (sTaT1) while promoting that of sTaT3. we 
have recently demonstrated that protein tyrosine phosphatase, non-receptor type 11 (PTNP11, best known as shP2), a 
phosphatase that operates downstream of eGFr, is responsible for the dephosphorylation of active sTaT1 and for the 
inhibition of the antigen-processing machinery (aPM), hence favoring tumor immunoescape. Thus, eGFr signaling may 
skew the tumor microenvironment to suppress cellular immune responses.e27091-2  OncoImmunology  Volume 2 Issue 12
transcription 1 (STAT1).1,3,4 Interestingly, 
this phenomenon can be counteracted by 
interferon gamma (IFNγ) treatment as 
well as by the inhibition of SHP2, which 
is actually overexpressed by HNSCC 
cells.5 We have recently shown that the 
depletion of SHP2 favors STAT1 activa-
tion, in turn promoting the expression of 
APM components, MHC class-I restricted 
TAA presentation and activation of TAA-
specific CTLs.5 In addition, the SHP2-
mediated suppression of STAT1 signaling 
inhibits the production of TH1 cytokines 
by HNSCC cells, since SHP2 inhibition 
stimulated the secretion of interleukin 
(IL)-12p70 as well as of IFNγ-dependent 
chemokine (C-X-C motif) receptor 3 
(CXCR3)- and chemokine (C-C motif) 
receptor 5 (CCR5)-binding chemokines.5 
Interestingly, the activation of SHP2 by 
EGFR promotes mitogen-activated pro-
tein kinase (MAPK) signaling by increas-
ing the half-life of GTP-bound RAS.6 
Furthermore, it has recently been shown 
that the inhibition of v-raf murine sar-
coma viral oncogene homolog B (BRAF) 
enhances the IFNγ-mediated upregula-
tion of MHC class I molecules by mela-
noma cells.7 Hence, the upregulation of 
the MHC class I APM observed upon 
the depletion of SHP2 may be due to 
increased STAT1 activation as well as to 
the downregulation of MAPK signaling.
Remarkably, EGFR overexpression, 
which is frequent in HNSCC cells, not 
only reduces the level of phosphorylated 
STAT1 upon the activation of SHP2 but 
also stimulates the phosphorylation of 
STAT3, hence promoting the survival, 
proliferation and dissemination of can-
cer cells (Fig. 1).8,9 As a matter of fact, 
HNSCC cells also escape immunosurveil-
lance by promoting the establishment of 
a tumor microenvironment rich in immu-
nosuppressive lymphoid and myeloid cells. 
Such an immunosuppressive infiltrate 
forms in response to tumor-derived soluble 
factors including IL-6, IL-10, transform-
ing growth factor β1 (TGFβ1) and vascu-
lar endothelial growth factor (VEGF), all 
of which are secreted upon STAT3 activa-
tion.10 These cytokines negatively regulate 
the emission of pro-inflammatory danger 
signals, the maturation of dendritic cells 
(DCs) as well as the cytotoxic potential of 
CTLs.11,12 In addition, they can activate 
STAT3 in tumor-infiltrating immune 
cells, hence engaging a positive feed-
back circuitry that establishes a STAT3-
dominated tumor microenvironment.
HNSCC cells also overexpress IL-6 
receptor,  α (IL6RA) and IL-6 sig-
nal transducer (IL6ST, also known as 
gp130),13 leading to EGFR-independent 
STAT3 hyperactivation. These tyro-
sine kinase receptors recruit receptor-
associated kinases such as Janus kinase 
2 (JAK2), which catalyzes the activat-
ing phosphorylation of STAT3. STAT3 
Figure 1. signaling pathways involved in eGFr-mediated immunoescape. Interferon γ (IFNγ) promotes the phosphorylation of signal transducer and acti-
vator of transcription 1 (sTaT1), favoring the upregulation of multiple components of the MhC class I antigen-processing machinery and hence antigen 
presentation. Conversely, the activation of protein tyrosine phosphatase, non-receptor type 11 (PTPN11, best known as shP2) by epidermal growth factor 
receptor (eGFr) results in sTaT1 dephosphorylation as well as in the activation mitogen-activated protein kinase (MaPK) signaling, ultimately inhibiting 
MhC class I-restricted antigen presentation. similar to the interleukin-6 receptor (IL-6r), eGFr also promotes sTaT3 phosphorylation, stimulating the secre-
tion of immunosuppressive cytokines, such as interleukin-10 (IL-10), transforming growth factor β1 (TGFβ1) and vascular endothelial growth factor (VeGF).www.landesbioscience.com OncoImmunology  e27091-3
dephosphorylation is under the control 
of various protein tyrosine phosphatases 
(PTP). Therefore, STAT3 hyperactiva-
tion can be the result of increased activa-
tory signals and/or decreased inhibitory 
ones. As both EGFR and IL-6R promote 
STAT3 phosphorylation, simultaneously 
targeting both pathways by inhibiting a 
common downstream molecule stands 
out as the most logical strategy to reverse 
immunosuppressive activity of STAT3.
STAT1 and STAT3 play opposing 
roles in the course of oncogenesis and 
tumor progression, and an imbalance in 
STAT1 vs STAT3 signaling is observed in 
many epithelial cancers, in particular in 
settings in which EGFR simultaneously 
activates STAT3 while inhibiting STAT1 
via SHP2. STAT1 and STAT3 are indeed 
considered as an oncosuppressor and an 
oncoprotein, respectively. Therefore, the 
activation of STAT1 coupled to the inhi-
bition of STAT3 may underlie, at least in 
part, the therapeutic activity of EGFR-
targeting antibodies, such as cetuximab or 
panitumumab, and EGFR tyrosine kinase 
inhibitors like erlotinib or gefitinib. 
Inhibiting EGFR can enhance STAT1 
signaling, hence stimulating TAA presen-
tation, and inhibit STAT3, hence favoring 
the conversion of an immunosuppressive 
tumor microenvironment into an immu-
nostimulatory one. Clinical data obtained 
from cetuximab-treated patients as well as 
preclinical findings5 suggest that blocking 
the EGFR may synergize with targeted 
immunotherapeutics to shift the tumor 
microenvironment toward a STAT1-
dominated state in which malignant cells 
are susceptible to antitumor immune 
responses.
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